Florham Park, NJ, March 9, 2021
Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, announced the launch of Melphalan vial for injection 50mg, generic to Alkeran® and Progesterone capsules, 100mg and 200mg strengths, generic to Prometrium®.
“The launches of Melphalan vial for injection and Progesterone capsules are the latest examples of Xiromed’s commitment to bringing quality generic products to patients in the US. Xiromed has a robust portfolio of generic products across many therapeutic areas and dosage forms, and these two launches demonstrate our commitment to expanding our offerings in the injectable and soft gel capsule dosage forms,” commented Xiromed CEO, Narasimhan Mani.
Alkeran® for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. Annual market sales for Alkeran® and its generics for the twelve month period ending December, 2020 were $20.4 million, according to IQVIA™.
Prometrium® capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. Annual market sales for Prometrium® and its generics for the twelve month period ending December, 2020 were $74.8 million, according to IQVIA™.
Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/